HL Deb 09 January 1996 vol 568 c10WA
The Countess of Mar

asked Her Majesty's Government:

Whether they are aware of any reports which would indicate that patients taking FT, inhibitors such as Tagamet may be particularly vulnerable to the effects of exposure to very low levels of diazimon, and what research is done into the synergistic and potentiating effects of human drugs with organophosphates.

Baroness Cumberlege

The Government are not aware of any reports indicating a relationship between H2 inhibitors and vulnerability to low levels of diazimon or of any research in this area.